Targeted therapies and the treatment of non-clear cell renal cell carcinoma (Q26995391)

J. Dutcher

series ordinal

2

1 reference

language of work or name

1 reference

July 2013

1 reference

1 reference

24

1 reference

PubMed

issue

7

1 reference

PubMed

page(s)

1730-40

1 reference

2009 update on the classification of renal epithelial tumors in adults

PubMed

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Histopathological analysis of T1 renal cell carcinoma: Does presentation matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Renal medullary carcinoma: CT and MRI features

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Renal cell carcinoma: assessment of key pathologic prognostic parameters and patient characteristics in 47,909 cases using the National Cancer Data Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Treatment outcome for metastatic papillary renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Pathological, Immunohistochemical and Cytogenetic Features of Papillary Renal Cell Carcinoma With Clear Cell Features

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Chromophobe renal cell carcinoma: analysis of 53 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Chromophobe renal cell carcinoma: comprehensive analysis of 104 cases from multicenter European database

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Characteristics and prognosis of chromophobe non-metastatic renal cell carcinoma: a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

XP11.2 translocation renal cell carcinoma: clinical experience of Taipei Veterans General Hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Unclassified renal cell carcinoma: an analysis of 85 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

The genetic basis of cancer of the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Biological significance of c-met over expression in papillary renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Expression of KIT (CD117) in renal cell carcinoma and renal oncocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Overexpression of KIT in chromophobe renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Molecular subclassification of kidney tumors and the discovery of new diagnostic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Molecular classification of renal tumors by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Elucidation of the molecular signatures of renal cell carcinoma by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Systematic review of oncological outcomes following surgical management of localised renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Long-term outcomes of renal tumor radio frequency ablation stratified by tumor diameter: size matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT152

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT152

1 reference

Consolidated OpenCitations Corpus – April 2017

release_ilusdahtz5h2locelprjynde4a

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ilusdahtz5h2locelprjynde4a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

23625974

1 reference

Consolidated OpenCitations Corpus – April 2017